Bedrijfsoverzicht
Curis, Inc. is a biotechnology firm dedicated to the discovery and development of drug candidates aimed at treating human cancers within the United States market. The company operates within the broader healthcare sector, specifically focusing on the biotechnology industry, which entails high-risk research and development activities with the potential for significant regulatory hurdles. As of the latest available data, the company's market capitalization stands at $19.99M, while its annual revenue for the trailing twelve months is $9.44M, employing a workforce of 20 individuals. These valuation and revenue figures indicate that Curis, Inc. is a micro-cap entity with a relatively small operational footprint, suggesting that its financial stability is heavily dependent on the successful progression of its clinical-stage assets like Emavusertib.
Financiële gezondheid
The company reported a revenue of $9.44M over the trailing twelve months, yet it generated a net income of $-7,582,000 and an EBITDA of $-32,733,000. The substantial disparity between the positive revenue figure and the significant negative net income reveals a cost structure where operating expenses far exceed gross revenues, a common characteristic in early-stage biotechnology firms burning through capital for research. Free cash flow stands at $-10,457,375, which indicates that the company is currently converting its earnings into cash outflows rather than generating surplus liquidity, thereby limiting its immediate financial flexibility for organic expansion without external funding. The company's margins reflect this financial pressure: a gross margin of -199.7%, an operating margin of -665.2%, and a profit margin of -80.3%, all of which signal severe inefficiency or high burn rates relative to sales volume in the current period. On the balance sheet, Curis holds $5.06M in cash against $1.62M in debt, resulting in a debt-to-equity ratio of 29.62, which suggests a leveraged position given the negative equity context often found in pre-profit biotech firms. The current ratio is 0.49, indicating that the company's current assets are less than half of its current liabilities, which points to potential short-term liquidity challenges. Furthermore, the return on equity is listed as N/A due to the lack of traditional equity returns, while the return on assets is -67.2%, revealing that management is currently destroying value relative to the asset base rather than generating returns.
Waarderingsbeoordeling
Valuation metrics for Curis, Inc. present a complex picture due to its lack of profitability, with a trailing P/E ratio of N/A and a forward P/E of -0.52. The distinction between a non-existent trailing P/E and a negative forward P/E implies that the market is pricing in a continuation of losses or a fundamental inability to generate earnings in the near term. The price-to-book ratio is 1.18, suggesting that the market values the company slightly above its book value, which is an unusual premium for a company with negative earnings and significant losses. Alternative valuation metrics such as the price-to-sales ratio of 2.12 and an EV/EBITDA of -0.51 provide insight into how investors are valuing the firm based on sales generation rather than earnings power, highlighting the speculative nature of the investment. Price metrics show a 52-week high of $3.13 and a 52-week low of $0.49, indicating a trading range with extreme volatility. Without a specific current price provided in the facts, the relative position cannot be calculated as a percentage, but the wide spread between the high and low underscores the asset's sensitivity to market sentiment. The beta is 3.14, which means the stock's price volatility is significantly higher than the broader market, amplifying both potential gains and losses relative to a standard market index.
Growth & Income
Revenue growth year-over-year is -66.0%, while earnings growth is N/A, indicating that the company is currently contracting its top line and has no earnings growth trajectory to analyze. The fact that revenue is declining while the company remains in a loss position suggests that the burn rate may be increasing relative to shrinking sales, or that the revenue base is eroding without new product launches. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute income to shareholders, implying that any available cash or potential future earnings are retained for reinvestment into research and development. Consequently, the overall growth and income profile is characterized by negative revenue momentum and a complete absence of dividend income, relying entirely on the future commercial success of its drug candidates to reverse its financial trajectory.